Connect with us


Mydecine Innovations Brings Onboard Ethica CRO As A Research Contract Partner For Phase 2A PTSD Clinical Trials



Mydecine Innovations Group Inc (OTCMKTS:MYCO) looks forward to starting its Phase 2A PTSD clinical trials and sees ethica CRO (“ethica CRO”) as an ideal partner. After considering its excellent work towards introducing a new ethical dimension to clinical research, the business giant has chosen the partner.

CRO’s accreditations

The other thing that makes the partner ideal is that it became the first CRO to receive accreditation as a significant player in a human research protection program conducted back in 2006. Some people would also see the CRO getting accreditation from about three accrediting bodies as a significant achievement and qualification for the new partnership.

The CEO of Mydecine Innovations Group, Josh Bartch, applauded the move to collaborate with such a top-class partner. He hopes that the CRO’s outstanding expertise in managing clinical studies will be a great addition to their success in the upcoming Phase 2A PTSD clinical trials.

The official sees the move to bring onboard the new partner to show their outstanding preparations towards discovering how the brain reacts to psychedelics. The parties will also be looking to establish what a psychedelic experience could cause in biological underpinnings.

Mydecine wants to push its clinical development to the pinnacle, and it will be counting on its partner’s unparalleled experience in wide-ranging trials. Ethica CRO is known for its deep clinical expertise and will help a lot with the trial preparations.

Jensen’s perspective

The Managing Director of ethica CRO Murray Jensen is happy about the impressive mental health treatment changes. He terms Psychedelics and psychedelic-assisted therapies as some of the game-changers as they continue to progress with their innovation drive.

Mydecine is pleased to announce its partnership with Microdose Psychedelic Insights, a move that will see the two focus on unveiling a free, live webinar series. Reports show that the series will entirely focus on the Renaissance of Psychedelics.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.


Business1 week ago

NewAge Inc. (NASDAQ:NBEV) Expanding Its Operations In Europe As Lucim™ Gets Recognition As A Safe Skincare Product

Post Views: 359 NewAge Inc. (NASDAQ:NBEV) announced a record net revenue increase in Europe, record attendance at its virtual events,...

Business2 weeks ago

ILUS International Inc. (OTCMKTS:ILUS) Appoints New Marketing Director Dejana Radonjic To Help With Global Marketing

Post Views: 320 ILUS International Inc. (OTCMKTS:ILUS) seems more focused on making new acquisitions, with about two accomplished within its...

Business2 weeks ago

Conservative Broadcast Media Journalism (OTCMKTS:CBMJ) Reports Revenues Of $2.4 Million In 2020

Post Views: 389 Conservative Broadcast Media Journalism (OTCMKTS:CBMJ) posted a robust growth of 118% YoY to $2.4 million in 2020. Development...


Cannabics Pharmaceuticals (OTCMKTS:CNBX) Initiates RCC-33 Dose-Response Study, And Cresco Labs (OTCMKTS:CRLBF) Launches Wonder Wellness Gummies

Post Views: 358 Cannabics Pharmaceuticals (OTCMKTS:CNBX) has announced that it will initiate a Dose-Response in-vivo Study in mice whose data...


Curaleaf Holdings Inc. (OTCMKTS:CURLF) Rebrands And Opens New Locations In Pennsylvania And Illinois

Post Views: 397 Curaleaf Holdings Inc. (OTCMKTS:CURLF) has announced new Curaleaf branding for its recently acquired retail locations and the...

Business2 weeks ago

Generex Biotechnology Corp’s (OTCMKTS:GNBT) NuGenerex Immuno-Oncology Responds To FDA Regarding Its Paediatric-Focused COVID-19 Vaccine

Post Views: 368 Generex  Biotechnology Corp’s (OTCMKTS:GNBT) subsidiary NuGenerex Immuno-Oncology has announced the submission of a response to the FDA’s...